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Abstract
This article describes the knowledge-based system TheMPO (TherapyManage-
ment in Pediatric Oncology), which supports protocol-directed therapy planning
and conguration in pediatric oncology. TheMPO provides a semantic network
controlled by graph-grammars to cover the dierent types of knowledge relevant
in the domain, and oers a suite of acquisition tools for knowledge base author-
ing. Medical problem solvers, operating on the oncological network, reason about
adequate therapeutic and diagnostic time-tables for a patient. Furthermore, a cor-
responding patient record, also based on semantic networks and graph-grammars,
has been implemented to represent the course of therapy of an oncological patient.
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1 Introduction
The treatment of childhood cancer is characterized by the application of stan-
dardized protocols containing diagnostic criteria, detailed instructions about
chemo- and radiotherapy, and recommendations concerning the management
of toxicity (e.g., [1]). Due to these protocols, the prognosis of malignant child-
hood diseases has improved signicantly during the last two decades [2,3].
However, this has gone hand in hand with an increasing complexity of treat-
ment, and has led to new challenges and burdens for the medical sta, es-
pecially with regard to medical decision making and documentation. As a
former program, restricted to the subtask of chemotherapy calculation in this
domain (Catipo [4]), has shown encouraging results in the clinical routine,
it has been assumed that a larger knowledge-based system, providing a for-
mal representation of the protocols as its core and therefore being able to
support protocol-directed therapy and documentation, could be helpful for
the medical sta involved in therapy. Therefore, the Department for Medical
Statistics and Documentation of the University Hospital Mainz, Germany, has
developed the knowledge-based system TheMPO 1 (Therapy Management
in Pediatric Oncology), providing a) graphical tools for the acquisition of
protocol knowledge, and b) problem-solving modules which determine an ap-
propriate (sub)protocol for a given patient, and which congure and modify
this protocol according to the patient's initial condition and his individual
response during long-term treatment.
First of all, in the remaining part of this section, the structure of pediatric
cancer therapy is analyzed. In section 2, three acquisition tools are introduced,
which enable the physician to specify protocol knowledge, including a) time-
tables for chemo- and radiotherapy, b) therapy branches and branching points,
and c) rule knowledge for therapy modication. The internal representation
approach, which is based on semantic networks realized through attributed,
directed and labeled graphs and graph-grammars, is described in section 3.
Section 4 outlines the medical problem solving process which uses the protocol
knowledge and the patient's data to suggest patient-adapted therapy time-
tables. The corresponding time- and context-oriented patient database, which
is based on attributed graphs and graph-grammars too, is described in section
5. After having addressed implementation details in section 6, an overview
concerning related work is given in section 7. Strengths and weaknesses of the
current approach together with future research topics in the context of the
TheMPO-project are discussed in section 8. As an initial remark, it has to be
stated, that - for better presentation - some of the domain examples originating
from protocols have been slightly simplied or modied (especially in section
1The TheMPO-page can be found at
http://www.Uni-Mainz.DE/FB/Medizin/IMSD/TheMPO/TheMPO eng.html
2
2 and 4), to clarify the knowledge representation and processing done by the
system. Therefore, only the original protocols should be used as knowledge
source for the domain of pediatric oncology.
1.1 Protocol Structure in Pediatric Oncology
In pediatric oncology, protocols typically cover time periods from 6 months up
to 2 years, including initial diagnostics and assignment to dierent risk groups
and therapy branches, intensive inpatient chemo- and radiotherapy phases for
tumor remission, consolidation therapy, and outpatient long-term therapy to
avoid tumor recurrence. To analyze whether a new drug or drug combination
is able to improve the prognosis, protocols often randomize patients of a parti-
cular risk group and assign them to dierent, competitive therapy branches. A
typical chemotherapy may last from 4 days (chemotherapy N1 of the neurob-
lastoma protocol) up to 9 weeks (chemotherapy I of the acute lymphoblastic
leukemia protocol ALL-BFM95), and may consist of 3 cytostatic drugs (N1)
up to 10 drugs (HR-2 of ALL-BFM95). Depending on the initial prognosis,
intensive chemotherapy units may be administered up to 4 or 8 times sequen-
tially, alternating with phases of recovering. Figure 1 illustrates the structure
of a typical protocol, and gure 2 describes the internal structure of a chemo-
therapy.
Furthermore, a knowledge-based system in this domain has to deal with the
following types of temporal constraints and relationships:
{ Exact quantitative relations: Folin acid rescue should be given exactly
42, 48 and 54 hours after the Methotrexate-infusion has started.
{ Inexact quantitative relations: Chemotherapy of type III (of brain tu-
mor protocol) should start not earlier than 2 weeks after the start of the
preceding chemotherapy of type II, but not later than 3 weeks.
{ Qualitative relations: Electrocardiography and echocardiography should
be done before the rst and third administration of Adriamycin.
In addition to this time-table knowledge valid for a patient collective, protocols
also contain rule knowledge supplementing or overwriting the standard time-
tables, such as:
IF initial CNS-inltration has been observed
THEN give Mtx intrathecal additionally at day 18 and 27 (and not only
at day 1,12,33,45,59).
In summary, a knowledge-based system in the domain of pediatric oncology
has to be able to represent time-tables of chemo- and radiotherapy, long-
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Fig. 1. Temporal structure of the protocol for acute lymphoblastic leukemia
(ALL-BFM-95). After the initial diagnosis, the patient is assigned to one of the
three risk groups (SR = standard risk , MR = medium risk , HR = high risk). In
the assignment criteria boxes at the left side, a `+' indicates an AND-, a circle
an OR-conjunction of the conditions (Pred-GR resp. Pred-PR means Prednisone
Good Response resp. ...-Poor Response). t(9;22)/BCR-ABL ... in the HR-box are
abbreviations for specic genetic ndings indicating critical leukemia subtypes.
I',I,M,MCA,IA and HRx' are types of chemotherapy, the long bars at the right sym-
bolize types of long-term chemotherapy for recurrence avoidance. Radiation ther-
apy is indicated by 'n Gy' . G-CSF is the Granulocyte-Colony-Stimulating-Factor .
Reproduction of graphic by kind permission of the central commission of the
ALL-BFM-95 protocol (H. Riehm et al.).
edge for patient-adapted therapy modication, and temporal constraints con-
cerning the duration of therapy-intensive and therapy-free intervals. As espe-
cially modern chemotherapy is based not only on the drugs themselves and
their dosages, but also on the complex and sophisticated temporal interac-
tion structure of these drugs, special attention has to be paid to the adequate
representation and processing of temporal knowledge.
2 Knowledge Acquisition
To dene the structure of oncological protocols, TheMPO provides three





i.th. at day 18 and 27
Fig. 2. Time-table of a chemotherapy (type I) of the ALL-BFM95 protocol (the
labels PRED, ..., MTX are abbreviations for chemotherapy drugs). The bar rep-
resenting the time-table of Prednisone (=PRED) indicates that the dosage of
this drug should be increased gradually up to the daily dosage of 60 mg/m2 during
the rst 7 days, and should be reduced during the last 9 days. Reproduction of
graphic by kind permission of the central commission of the ALL-BFM-95 protocol
(H. Riehm et al.).
the physician. The rst tool, called TherapyEditor, enables the physician
to dene cytostatic infusions and supportive medications, and to group these
therapy elements together to dierent types of chemotherapy. Furthermore,
phases of radiotherapy can be specied with the TherapyEditor as well.
With the second tool, called ProtocolEditor, the physician denes se-
quences of chemotherapy and radiotherapy phases which have been specied
with the TherapyEditor. This includes the denition of constraints con-
cerning the intervals between the successive phases, and the specication of
stratication (branching) points. The third tool, the RuleEditor, which can
be invoked from both of the above tools, enables the physician to dene rule
knowledge needed for instance to specify modication or discontinuation cri-
teria valid for a particular chemotherapy, or to dene branching criteria for
stratication points. All tools internally operate on the same semantic net-
work, each tool having write access to a well-dened subnet. The following
three sections briey illustrate the functionality of these acquisition tools.
The structure of the underlying semantic network is described in section 3.
2.1 TherapyEditor
This tool is used to specify the basic components of a protocol, including
cytostatic medications and types of chemotherapy. Figure 3 illustrates the
specication of the internal temporal structure of the chemotherapy N1 within
the neuroblastoma protocol.
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Fig. 3. Denition of the time-table of the chemotherapy N1 (neuroblastoma proto-
col).
With the window shown in this gure, the physician has specied that the
duration of this chemotherapy should be exactly 4 days; the infusions DDP
(=Cisplatin) and VP16 (=Etoposide) are given every day. VDS (=Vin-
desine) is given only at the rst day. The integer `1' in the `Pre-Administration'-
eld of the VDS-column indicates that this drug should be given exactly one
hour before the actual beginning of the chemotherapy, as this drug is stopping
the cell division at a stage sensitive for the other cytostatic drugs. The entry
`100%' species that each drug is given with 100 percent of the daily dosage
at every day of the administration (with exception of day 1 of the DDP-
application, where only 50 percent of the daily dosage are given to accustom
the child to this drug). At the upper right, an icon has been assigned to this
chemotherapy; this icon will be used as an identifying symbol by the Proto-
colEditor. Detailed information about the involved drugs (such as the daily
dosage or the run-time, or whether a drug should be given intramuscular, oral









Fig. 4. Graphical denition of a part of the neuroblastoma protocol with the Pro-
tocolEditor (see text for details).
2.2 ProtocolEditor
The ProtocolEditor enables the physician to dene sequences of chemo-
therapy and radiotherapy phases which have been specied with the The-
rapyEditor described above. This covers the specication of constraints
concerning the intervals between the successive phases, and the denition of
stratication points specifying that { depending on the patient's individual
data { one of several therapy branches should be selected. The gures 4 and
5 illustrate the interactive process of specifying the temporal structure of a
typical protocol.
The palette at the top of gure 4 provides symbols representing the dierent
types of chemo- and radiotherapy which have been dened with the Thera-
pyEditor. This symbols can be dragged to the worksheet beneath to specify
the structure of the protocol. Here the physician has specied that, rst of all,
a surgical phase is applied (symbol OP). A stratication point (symbol `_'
for `OR' ) indicates, that after this surgical unit, the patient is assigned to ex-
actly one of several therapy branches, depending on his individual laboratory







Fig. 5. Graphical denition of a cyclic structure.
edge specifying the stratication criteria has not yet been dened (this can be
done with the RuleEditor in one of the next steps). Temporal relationships
between protocol components are acquired by dragging an edge between two
symbols. The user then is prompted to ll a form containing the quantitative
information. In gure 4 the physician is specifying that the chemotherapy of
type N2 (upper branch) should start not earlier than 4 weeks after the be-
ginning of the preceding N1-therapy, but not later than 5 weeks. The symbol
`^' (for `AND') in the bottom branch means that the patient should undergo
the N1/N2-sequence and a parallel radiotherapy of the metastases (RT-M).
Fig. 5 illustrates the denition of a cyclic protocol structure. In this gure,
it is dened that the sequence D1/D2 should be given 6 times, and that the
therapy then should terminate. Rule-based termination criteria, such as `IF
Complete remission of tumor THEN terminate cycle', can be dened with
the rule editor described in section 2.3. Furthermore, the physician can in-
spect the components of a chemotherapy by selecting the associated symbol
and calling an inspector. In Fig. 5, the inspector is informing the user that




Fig. 6. Graphical denition of a rule with the RuleEditor.
2.3 RuleEditor
The RuleEditor is used to dene rule knowledge. It covers the denition of
local modication or discontinuation criteria valid in the context of a particular
chemotherapy, and the specication of initial stratication points and termi-
nation criteria in therapy cycles. The RuleEditor can be called both from
the TherapyEditor and the ProtocolEditor, and exports the specied
rule to the calling module, which then stores the rule in the appropriate part of
the internal semantic network (see section 3 for more details). Figure 6 shows
the specication of a rule valid in the context of the chemotherapy N1.
In this gure, the rule is dened that whenever the creatinine-clearance value is
less than 70 ml/min during a chemotherapy N1, the drugCisplatin should be
discontinued (as nephrotoxicity { indicated by abnormal creatinine-clearance
values { is one of the serious side eects of Cisplatin). This rule is specied
by a) selecting the appropriate concepts (such as drug names, or laboratory
parameters) in a concept browser at the bottom of the window, and b) by
9
dragging the selected concepts to a worksheet above where they are used
to assemble the rule. The rule then is subjected to a syntactic check and
transformed to the internal rule notation. The calling editor, which in this
case has been the TherapyEditor, imports the rule, and stores it in the
subnet representing the N1-chemotherapy.
3 Protocol Representation
For protocol representation, a semantic network approach has been chosen.
In TheMPO, this approach is based on labeled, directed, and attributed
graphs 2 . A protocol component such as a cytostatic infusion, a chemothe-
rapy, or a surgical unit is represented through a labeled node (e.g., with the
label Infusion); information such as the names of the cytostatic and support-
ive ingredients, or the daily dosage of a cytostatic component, is stored in
attributes associated with the particular label. From the object-oriented point
of view, the node labels and their associated attributes form a class hierarchy,
the instances of the particular classes being the nodes of the semantic network.
Relationships between protocol components, such as temporal or component-of
relations, are expressed via labeled and directed edges connecting the nodes
in the network. Figure 7 shows the inheritance hierarchy of the attributed
node labels, and the gures 8 and 9 illustrate the internal representation of a
neuroblastoma protocol.
One basic problem arising in connection with complex network-oriented data
structures is the formal description of the class of legal networks. A next-
edge may point from a TherapyPhase-node to another, but it is inadequate
to connect a Section-node with a RuleSet-node. To formally dene the class
of legal protocol networks, a graph-grammar approach has been used. Graph-
grammars are a calculus to formally describe the legal manipulations on graphs
by dening a nite set of so-called graph productions. This technique, which
has its roots in the graph-theory and software-engineering community [5{7],
has already been used to specify the semantics of programming languages [8],
to build tools for computer-aided software engineering [7], and, in the domain
of medicine, for the modeling of medical dilemmas and decisions [9,10]. In the
following the theoretical background of the graph-grammar approach is briey
described; a detailed description of this calculus can be found in [11,12].
2 In the following, the terms semantic network and graph are used, in a way, as
synonyms. However, the term semantic network emphasizes the representational






















Fig. 7. Inheritance hierarchy of attributed node labels. Every node in the proto-
col network is an instance of one of the classes in this hierarchy. Abstract classes
which can't be instantiated directly are denoted by brackets. The dashed line in-
dicates the classes used by the ProtocolEditor, the other line shows the scope
of the TherapyEditor. All classes derived from the abstract class VisibleNode
denote objects which are visualized as graphical symbols on the worksheet of the































































Fig. 8. Part of the semantic network representing the neuroblastoma protocol. The
global temporal structure is represented by a subnet starting at node 4. The rst
therapy phase is a surgical intervention (indicated by the isOfType-edge leading to
the surgical subnet which contains the surgical components; this subnet has been
omitted here to save space). After that the patient is assigned to one of several
therapy branches depending on his individual data. The stratication criteria are

























Fig. 9. Part of the semantic network representing the structure of the chemotherapy
N1 of the neuroblastoma protocol. The TimeTable-node represents the time-matrix
specied in gure 3 in section 2, and the RuleSet-node stores rules { such as the
Cisplatin-rule in gure 6 { dealing with the modication of a therapy when side
eects and toxicity events are detected. An Infusion-node stores all information
about a particular infusion, such as the daily dosage and the age dependencies, the
solvent conguration and the run-time.
3.1 Graph-Grammars
The basic construct of a graph-grammar is the so-called graph production,
describing a valid unit of graph manipulation. A production P again is a
graph providing substructures for the deletion, generation, and embedding of
nodes and edges. Figure 10 shows a simple graph operation of the protocol
grammar.
This production would be interpreted as follows:
{ The parts Del (for the Deletion of nodes and edges) and Det (for Deter-
mined Embedding) specify where the production should take place in the
current host graph (i.e. the protocol graph). In this example, the existence
of a VisibleNode-node (or a node with a sublabel of VisibleNode { such
as TherapyPhase), and an incoming marks-edge with a Cursor -node as its
source node, has to be determined. The Cursor -node is used to achieve
the unambiguity of a matching region in a host graph, and is usually set
by the preceding graph production to indicate where the next production
should take place. For instance, a Cursor -node may point to the node repre-
senting the chemotherapy currently being edited by the TherapyEditor.
Furthermore, to avoid the problem of several matching regions in the host graph,
productions can be provided with additional constrains for the starting region.
In so-called preambles it is possible to specify that some node attributes of the
matching region must fulll specied conditions, or P will not be processed.
{ If the structure specied by Del and Det does not exist, the production is
aborted. Otherwise, the following steps have to be done:
 Delete the structure specied in Del . In the case of Figure 10, remove the



















Body: 2.index = newIndex; 2.cycleName = name; 2.frameRect = frame;
           2.cycleImage = image; 2.cycleEnd = end;





GraphProd_AddTherapyNode( in  name:        String,
                                                       in  begin:        TempConstraint
                                                       in  end:           TempConstraint);
Body: 2.phaseName = name;  2.phaseEnd = end; 3.entryTime = begin;
Fig. 10. Sample graph production of the protocol graph grammar (with indeter-
minate embedding = ;), which is launched by the TherapyEditor and adds a
new therapy phase node to the oncological network. The string at the top (Graph-
Prod... ) is the head of the production with the input parameters name, begin and
end ; TempConstraint is a structure to represent the temporal constraints aect-
ing the begin or end of a phase (the little window `Start of N2' in gure 4 contains
an example for temporal constraints). The values of the input parameters then are
assigned to the attributes of the nodes in the Body-statement (see text for more
details). For a more complex graph production with indeterminate embedding 6= ;,
see gure 13 in section 5.
 Process the Gen-part of the production (for Generation of nodes and
edges). In this case, create a TherapyPhase-node and an EntryTime-node,
and connect them with a hasEntryTime-edge (in the specied direction).
 After that, embed the new nodes into the existing host graph. This em-
bedding is processed in two steps. The rst step is described by the sub-
structure called Det (for Determined Embedding), and denotes an embed-
ding which is carried out anyway (therefore determined), as the substruc-
ture Det does exist in the graph (otherwise, the production would not
have been launched). In this example, the determined embedding consists
of simply connecting the TherapyPhase-node with the VisibleNode-node
through a next-edge, and of linking the EntryTime-node to the Visible-
Node-node via a nextEntryTime-edge.
 The second part (Ind for Indeterminate Embedding) describes an em-
bedding which depends on the current structure of the surrounding host
graph, and therefore is not known in advance. In this simple example, the
Indeterminate Embedding is empty. Figure 13 in section 5 provides a more
13
complex production with indeterminate embedding 6= ;.
{ The last step of this production processes the attribution commands in the
Body-Statement (e.g., the assignment of the value of the parameter begin
to the entryTime-attribute of node 3 (the new EntryTime-node).
More generally and formally, and given a set of edge labels E and attributed
node labels N , a graph-grammar is a triple (S; P; T ), where
{ S is a start graph,
{ P a nite set of graph productions, and
{ T a nite set of graph transactions.
A start graph S is a graph built from elements of N and E, the attributes
of all nodes of S having dened values. The start graph is generated when a
new protocol is dened with the ProtocolEditor, and provides a tree to
organize and group the protocol components and time-tables. Graph produc-
tions dene the valid basic manipulations on a graph and have the structure
shown in gure 10. Furthermore, graph productions can be grouped together
to graph transactions. A graph transaction is an indivisible sequence of graph
productions which has to be carried out entirely or { if an error occurs during
the processing of the production rules { has to reset the graph to the state
before the transaction was launched. By using transactions inconsistent states
of the protocol graph can be avoided.
Formally, a protocol graph is valid if it can be derived from the start graph
S by using transactions only of the protocol graph-grammar. In practice, the
validness of the protocol network and especially the referential integrity is
enforced by allowing external modules only to call public transactions of the
grammar. The graph-grammar approach introduced and illustrated above has
been used to model and develop the oncological knowledge base of TheMPO.
All together, the recent protocol graph-grammar consists of 36 generic graph
productions and 30 graph transactions which can be parameterized with node
and edge labels and attribute-values.
In conclusion, it can be stated that graph-grammars are an appropriate calcu-
lus to formally describe complex graph manipulations which have to be pro-
cessed during protocol acquisition. Entity-Relationship models, for instance,
which also specify the valid structure of graphs, don't provide a formalism
to describe the dynamics of network transformation processes. The graph-
grammar approach introduced has been used to describe the structure and
the dynamical behavior of the protocol graph formally on a high level of ab-
straction without having to take care of implementation details. With this
approach conceptual errors can be avoided or detected at an early stage. The
graph-grammar model for instance only claims that edges between nodes are
represented explicitly ; it does not make any assumptions concerning the ques-
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tion how these edges are realized in detail (e.g., through adjacency-matrices
or adjacency-lists). This is an implementation issue (see section 6) as well as
the realization of graph transactions with the low-level transaction mechanism
of a database.
3.2 Rule Representation
Rules which have been specied with the RuleEditor described in section
2 are internally stored in Clips, which is a rule-based language with forward-
chaining inference [13]. For each ChemoTherapy-node in the protocol network,
there exists a RuleSet-node which is connected with the ChemoTherapy-node
via a hasComponent-edge, and which stores rules valid only in the context of
this particular chemotherapy (see gure 9 as well). If a patient passes through
the chemotherapy represented by this ChemoTherapy-node, the relevant rules
can easily be retrieved by accessing this associated RuleSet-node.
4 Medical Problem Solving
To model the oncological problem solving process, a modication of the method
Episodic-Skeletal-Plan-Renement , based on the works of [14], has been used.
This problem-solvingmethod consists of the three subtasks Propose-and-Calcu-
late-Plan, Identify-Problem and Revise-Plan. These subtasks will now be de-
scribed briey.
4.1 Proposing and Calculating a Plan
When a pediatric patient is admitted to hospital after a cancer disease has
been diagnosed or a therapy-free interval has nished, the propose-plan mod-
ule reasons about the appropriate therapy to administer next. This is done
by exploring the semantic network described in section 3. If, for example, the
patient has recently nished a chemotherapy of type N1 and is then recovering
in a therapy-free interval, the problem-solver explores outgoing next-edges to
identify the next therapy phase, processes the temporal constraints in Entry-
Time-nodes to suggest the time for starting the next phase, and loads and
processes rules stored in RuleSet-nodes to determine whether the patient ful-
lls all criteria for starting the therapy phase. This problem solving process
can explicitly be launched by the physician for a given patient, or can be done
through a demon process scanning the patient database (preferably at night)
to determine which patients have to be prepared for which type of therapy.
15
Fig. 11. Suggestions of the medical problem solver for two (ctitious) patients.
Figure 11 shows the suggestions of the problem solver for two patients in the
database.
For the rst patient in this gure, who is currently recovering from the 1st
chemotherapy of type N2, the problem solver for example has suggested to
start the next chemotherapy (type N1) on 13 Sep 1995. The physician can
agree, disagree, or postpone the decision. If the button entitled with Expla-
nations ... is clicked, the problem solver a) invokes the ProtocolEditor to
load and view the relevant part of the protocol, and b) loads the individual
patient data which have led to the suggestion. In the box underneath, the
physician can inspect the diagnostic procedures which have to be done before
the patient enters the chemotherapy, and can add or remove procedures. If the
physician agrees to the suggestion of the problem solver (e.g., agrees that the
next chemotherapy should be of type N1 and should start at the suggested
date), a submodule is launched to calculate the patient-adapted daily dosages
of the drugs of the chemotherapy. The knowledge about the components of a
chemotherapy, its time-table and the daily dosages is retrieved from the subnet
shown in gure 9. Furthermore, portioning and event plans can be calculated
for the nursing sta, giving the information at which time the infusions have
to be administered, and which infusion rates have to be tuned in.
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To achieve transparency of the underlying medical reasoning, the problem-
solving process has been explicitly described with a CML-oriented language.
CML (= Conceptual Modeling Language) [15] is a semi-formal specication
language to describe the expertise model of knowledge-based systems, and
has been developed within the CommonKADS-research project (e.g., [16]).
CML provides constructs for the specication of ontologies, basic inference
steps, and complex tasks. The following example shows the specication of
the task T ProcessRuleBasedAssignment , which is a subtask of the propose-
plan-module, and which determines an appropriate risk group for a particular
patient (the prex T denotes a task , the prex I an inference):
task T ProcessRuleBasedAssignment;
task-denition:
goal: derive appropriate (risk-group) assignment
input:
patient-id: a variable storing the patient identier
protocol-id: identier of protocol the patient is treated with
assign-id:
assignment identier within the protocol
(a protocol may have more than one assignment)
output:
assignment-derived:
the assignment which has been derived (e.g., MR=medium risk group)
(is NIL if assignment has not been possible)
record-access-results:
a list containing information for example about
missing or uncertain patient data in the record
spec:
This tasks tries to derive an appropriate assignment for the patient identied by
patient-id and currently undergoing the protocol protocol-id . Therefore, the assignment
rules stored in the protocol subnet identied by assign-id are processed, and relevant
information about missing or uncertain data, or data which do not exactly match the
temporal requirements of the rules, is stored in the list record-access-results.
task-body:
sub-tasks: ... (list of the subtasks used)
additional-roles:
assign-rules: list of assignment rules to be processed
tmp-rule-id: identier of current rule
tmp-result: high-level result of current rule processing (e.g., PREMISE FALSE)
tmp-record-access-results:
detailed information about missing or uncertain
data concerning the current rule evaluation
control-structure:
T ProcessRuleBasedAssignment(patient-id, protocol-id, assign-id
  > assignment-derived, record-access-results) :=
assignment-derived := NIL;
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I GetAssignRuleIds(protocol-id, assign-id   > assign-rules)
// get assignment rules from knowledge base
FOR tmp-rule-id IN assign-rules DO // for each rule ...
T ProcessRule(patient-id, protocol-id, assign-id, tmp-rule-id
  > tmp-result, assignment-derived, tmp-record-access-results)
IF (tmp-result == PREMISE TRUE) THEN // rule red ...
// overwrite former, irrelevant record access results,
// as assignment has been successful, and exit task ...
record-access-results := tmp-record-access-results;
EXIT-FOR-LOOP
ELSE // PREMISE FALSE or UNDECIDABLE
// add information about data responsible for PREMISE FALSE,




NEXT tmp-rule-id; // next rule ...
The task T ProcessRule is the central subtask invoked from T ProcessRule-
BasedAssignment . This subtask does not only process the assignment rule
itself by communicating with the internal Clips-interpreter, but collects and
maintains all relevant information concerning the patient data accessed during
rule processing. When T ProcessRule has nished, this information is repre-
sented in the output-list tmp-record-access-results, which provides a structured
entry for every patient parameter accessed during rule processing. To illustrate
this, the following typical assignment rule is used as an example:
IF risk factor 3  0:8 at day 1 (of initial chemotherapy) AND peripheral
leukemia cells < 1000 at day 8 AND blast cells in bone marrow < 5 percent
at day 33 AND ...
THEN assign patient to risk group MRG
Depending on the data situation in the patient record, the list tmp-record-
access-results would provide information about the following rule processing
`events':
(i) Unavailable data:
For example, tmp-record-access-results may store that there is NO in-
formation at all about the number of peripheral leukemia cells in the
record, and that therefore the rule could not have been applied. Informa-
tion about missing data may be irrelevant as other assignment rules may
have been able to re, but this information becomes important for the
physician, if NONE of the rules has been able to conclude a risk group
for the patient. In the latter case, the task invoking T ProcessRuleBased-
3The risk factor is a parameter measuring the initial number of peripheral blast
cells, and the degree of initial hepato- and splenomegaly.
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Assignment would process the output list record-access-results (which is
a collection of the tmp-record-access-results-lists), and would, for exam-
ple, detect that the assignment has failed because of a missing leukemia
cells value required by each of the rules. Therefore, an alert would be gen-
erated informing the physician that this parameter should be inspected
as soon as possible.
(ii) Temporal mismatch:
Because of the organizational and medical complexity of the diagnostic
and therapeutic procedures, and because of the patient's medical indi-
viduality, a patient parameter { although available in the record { may
not exactly match the temporal constraints of the rule, e.g., the blast
cells of the bone marrow may have been inspected on day 31 instead of
day 33. Therefore, to avoid decisions based on data being to old in the
current clinical context, the temporal match is measured in the following
way during rule processing:
{ Let Fi denote the nding parameter i appearing in the premise of a rule
R with n ndings (e.g., Fi = `blast cells in bone marrow (in percent)').
{ Let tFi denote the time point for which Fi is requested (e.g., tFi = day
33). The granularity of time depends on the particular parameter and
the specic context of the rule; in the domain of pediatric oncology,
days can be viewed as the central time units. However, in particular
situations such as the application of the drug Methotrexate and
the corresponding folin acid rescue, time has to be modeled on the level
of hours.
{ Let Pi denote the corresponding patient parameter (and its value) in
the record, and let tPi denote the time point of inspection of Pi (e.g., Pi
= `blast cells in bone marrow = 4 percent' have been examined on tPi
= `day 32'). If there are \competitors" Pi
1; Pi
2 with j tFi  tPi1 j=j tFi 
tPi2 j, then the systems usually selects the most recent value Pi
j(j 2 1; 2)
available in the patient database 4 .
{ Let tolFi;tFi ;C denote the temporal tolerance limit of Fi at tFi in the cur-
rent protocol context C. For example, if tFi = `day 33' and tolFi;tFi ;C =
2 (days), then tPi = 30 would be interpreted in the way that the pa-
rameter Pi is too old to be considered valid for rule R. The value of
tolFi;tFi ;C strongly depends on the particular context C; if, for exam-
4However, there are situations where the older value has to be used. For instance,
if a leukemia assignment rule requires a hematological parameter F at day 30, which
is the last day of an initial chemotherapy, and if there are values of F only available
for day 28 and day 32, it may be necessary to consider the older value, because
this value does reect the patient's hematological situation during chemotherapy
much better than the one after the chemotherapy, and because the assignment rule
uses the patient's initial chemotherapy response { measured by F and being an
important prognostic factor { for risk group assignment. Exceptions like this are
explicitly stated in the knowledge base.
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ple, Fi is a hematological parameter, tolFi;tFi ;C usually is signicantly
smaller during a chemotherapy than during a recovering phase, because
of the massive hematological side eects of the chemotherapy. The par-
ticular value of tolFi;tFi ;C is retrieved from the knowledge base during
rule processing.
{ Then, the degree of temporal matching between Fi and Pi in a context
C is measured through:
TM(Fi; Pi; C) =
8><
>:






This term is 1, if tFi = tPi , and decreases if the dierence di =j tFi tPi j
between tFi and tPi increases. If a parameter has a relatively small
temporal tolerance limit, di is weighted stronger than if there is a larger
tolerance limit.
{ If Fi1 ; : : : ; Fij is the subset of nding parameters F1; : : : ; Fn of rule R
for which the corresponding Pi1; : : : ; Pij would fulll the premise of R,
then the temporal match of Pi1; : : : ; Pij is measured through:





Furthermore, if cPi 2 [0; 1] denotes the certainty of the patient param-
eter Pi, then the temporal/certainty match of Pi1; : : : ; Pij is measured
through:
TCMR;Pi1 ;:::;Pij = 
ij
k=i1
TM(Fk; Pk; C)  cPk
Certainty factors occur relatively seldom in the domain of protocol-directed
oncology therapy, but there are several documentation slides where the
physician can label a nding for example with certain, nearly sure, unsure
and completely uncertain. Internally, this labels would be represented, for
instance, as 1; 0:75; 0:5; 0:25.
If T ProcessRule processes a rule R with nding parameters F1; : : : ; Fn, it rst
inspects whether there is a patient data combination Pi1 ; : : : ; Pij fullling the
premise of R, and checks whether the match TCMR;Pi1 ;:::;Pij is larger than a
given threshold t. If yes, the match is considered to be sucient, and the rule
res, and the patient is assigned to the risk group in the conclusion of R. If not,
T ProcessRule selects another combination Pj1; : : : ; Pjm fullling the premise
of R from the record, and again calculates TCM . This is done until a patient
parameter combination is found which fullls the premise of R, and where the
match TCM is larger than the threshold, or until no subset Pj1; : : : ; Pjm ful-
lling the premise of R is left. This algorithm is fairly simple, if the F1; : : : ; Fn
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are connected via AND-operators (as then there is { at best { only one com-
bination fullling the premise, i.e. P1; : : : ; Pn), but it becomes more complex
when there are OR-conjunctions in R. During rule processing, T ProcessRule
maps all information about temporal/certainty mismatches (and unavailable
data) to the output list tmp-record-access-results for further inspection.
4.2 Identify-Problem and Revise-Plan
As only a small number of patients passes long-term treatment without sig-
nicant side-eects, the internal problem-solver also has to identify problems
caused by the aggressive therapy, and has to decide whether to reduce or
discontinue a drug or drug combination, or whether to administer additional
procedures for toxicity management. Therefore, when a chemotherapy is given
to a patient, all rules stored in the RuleSet-node associated with this che-
motherapy are loaded by the internal Clips-interpreter. As dierent types
of chemotherapy are characterized by very dierent types of side-eects and
toxicity, and therefore require very specic therapy modication, this Rule-
Set-node represents rules which are valid only in the context of this particular
chemotherapy, and which have been specied with the graphical RuleEditor
of section 2.3. If patient data are entered into the record, the Clips-forward
chainer then processes the rules to detect abnormal and dangerous situations
(e.g., Creatinine-Clearance (ml/min) < 70 ), and suggests therapy modica-
tions such as Discontinue Cisplatin.
5 Patient Record
To store a patient's diagnostic data and course of treatment, TheMPO pro-
vides an electronic patient record as a source for retrospective inspection
and medical decision making. The main component of the underlying patient
model, which is based on semantic networks too, is a temporal subnet for the
representation of the course of treatment. This temporal net represents medi-
cal events such as the administration of a cytostatic drug through labeled, at-
tributed nodes, while temporal relationships are modeled with labeled edges.
Figure 12 for example shows the internal representation of a chemotherapy
administered to a particular patient.
The graph in this gure represents the administration of the chemotherapy
`I' within the leukemia protocol `ALL-BFM-95' (node labels are given inside
the boxes, attribute-values are placed beside the box frames). Days of treat-
ment and phases of chemotherapy are modeled explicitly, and not implicitly
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Fig. 12. Part of a patient graph.
tion of a cytostatic drug like Prednisone are related to PatDay-nodes via
hasEvent-edges. Furthermore, the subgraph shown in this gure represents
the causal context that Asparaginase has been discontinued on 15 March
1995 because of a serious hyperglycemia trend { described by the node la-
beled with PatTrend { which has developed since 14 March 1995. To control
the hyperglycemia, Insulin has been administered. The explicit representation
of becauseOf - or discontinuedBecauseOf -relationships enables the record to
directly answer questions such as Why has the obligate drug Asparaginase
been discontinued on 15 March 1995?
Similar to section 3, a graph-grammar approach has been used to manage
the complex graph transformations driven by information entry and medical
problem solving. Figure 13 shows a typical graph production of the patient
graph-grammar.
This production maps an inconsistency (detected by the physician or the prob-
lem solver) between two (diagnostic) data items { such as a new laboratory
value being not consistent to the current diagnosis { to the patient graph. The
production in this gure is parameterized with: (1) the labels of the conict-
ing nodes (rstPart and secondPart), (2) a string for additional comments
(description), and (3) the (day) time of detecting the inconsistency (time).
After having found the matching region in the patient graph, the produc-
tion generates an Inconsistency-node (node 5) and connects it with the two
conicting nodes (1 and 2) via inconsistencyPart-edges and the global Check-
List-node (determined embedding). After that, the indeterminate embedding










Body: 5.inconsistencyDscrpt = description; 5.contextKey = sys_contextKey();
          5.eventTime = time;
in  firstLabel:        NodeLabel,
in  secondLabel:   NodeLabel,
in  description:     String,





















Fig. 13. Sample graph production GraphProd EstablishInconsistencyContext of the
patient graph-grammar (see text for more details).
with MedEvent-nodes through becauseOf -edges. If this is not the case, the
production terminates successfully. Otherwise, the production connects every
detected MedEvent-node with the new Inconsistency-node via a weakens-edge
(if node 6 and 7 in the Ind-eld are identical, the weakens-edge is drawn only
once). The rationale behind this behaviour of the production is the following:
Whenever a MedEvent-node n (which may, for example, represent a medi-
cal conclusion or a therapeutic procedure) is based on one of the nodes 1 or
2, which are now integrated into an Inconsistency-context, then n should be
marked as a node whose medical validity is weakened by the detected incon-
sistency. Whenever the physician loads a window containing the information
represented by n, then the system will generate a message that there exists
a related data context which has been viewed as an inconsistency, and which
therefore (possibly) weakens the validity of n.
For the acquisition of semantic relationships such as the discontinuedBecauseOf -
edge between the Asparaginase-node and the hyperglycemia-node in gure
12, or the inconsistency context in gure 13, the TheMPO-record provides
graphical mouse-based tools which enable the physician to specify relation-
ships between medical events interactively. Figure 14 shows the acquisition of
a causal context during a chemotherapy N1 of the neuroblastoma protocol.
In this gure the physician species that he has reduced the Cisplatin-
infusion on 5 May 1995 because of a decreased creatinine-clearance detected
on 4 May 1995. This specication is done by dragging with the mouse from the
Cisplatin-window to the eld representing the data responsible for the re-
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Fig. 14. Screen dump of a graphical context specication (ctitious patient).
duction of the drug dosages (e.g., creatinine-clearance of 70 ml / min). During
the drag process a black arrow appears on the screen indicating the connection
between the two events. The program, which has registered that the dosages
have been reduced (by comparing the two dosage columns), assumes that the
physician wants to specify a reducedBecauseOf -context because he has con-
nected a drug-window with a window showing laboratory data. If the physician
conrms this assumption, the program generates a reducedBecauseOf -edge in
the patient graph between the Cisplatin-node and the creatinine-node.
Principally, the patient graph does not only allow the representation of con-
texts such as causal relationships and inconsistency clusters, but also reects
the main classes of queries occurring in the daily routine (i.e. interval-oriented
queries and parameter-oriented queries). This is done by linking every Med-
Event-node a) to the PatDay-node representing the day of the event (as shown
in gure 12) and b) by linking all nodes of a givenMedEvent-subclass together
via next-edges to represent the temporal course of a parameter (see gure 15).
Therefore, by using the query-oriented graph structure, querying of the pa-
tient graph is - in most of the cases - done in two steps: The query rst takes
advantage of the graph organization to reduce the search space, and then
uses OQL (= Object Query Language 5 )-commands of the database sys-




























































Fig. 15. The subgraph representing the table of contents (TOC) of a patient's record.
It is updated dynamically according to the specic procedures applied to the patient,
and serves as an entry point for queries to reduce search space (e.g. by jumping
directly to the FlowsheetRow -node for the hemogram reports when the hemogram
values are requested for a longer time-period). Furthermore, the user interface menu
of the patient's record is dynamically generated from this TOC.
tem to lter the node-lists in the reduced search space. If, for example, the
physician wants to inspect all cytostatic drugs for a given time interval such
as a particular chemotherapy, the query algorithm rst jumps to the node
representing this chemotherapy (by following the next-edges connecting the
PatChemotherapy-nodes), and then explores the subtree consisting of the has-
Day- and hasEvent-edges (by ltering the list of all MedEvent-nodes within
this chemotherapy with OQL). On the other hand, if for instance all time
intervals have to be found where the hemograms of the patient fulll a spe-
cic condition (such as leucocytes > 20000), the query jumps to the rst
PatHemogram-node in the patient record by using a subgraph representing
the patient-specic table of contents (see gure 15), and then uses OQL to
lter the PatHemogram-nodes and to determine the requested intervals. This
Data Management Group and implemented in most of the available object-
oriented database systems. It provides query capabilities similar to those of Sql,
with additional object-oriented features such as invoking object methods and lter-
ing their return values, and path expressions to navigate through object networks.
25
approach of additional query-oriented graph structuring has been considered
necessary, as the record of a patient usually covers long time periods (from 6
months up to two years), which implies hundreds of instantiations of a parti-
cular parameter on the time axis.
A detailed description of the context-oriented TheMPO-record can be found
in [17].
6 Implementation Issues
To implement the protocol and patient model, the object-oriented C++-
database Poet in the NeXTSTEP-environment has been used. To repre-
sent nodes and edges, the abstract data types Graph and GraphNode have
been implemented in C++/Poet. These data types encapsulate elementary
graph-functionality (e.g., adding and removing nodes and edges). For internal
graph representation adjacency-lists were used instead of adjacency-matrices
because the question in which contexts a node is embedded arises often. With
adjacency-lists { separated by incoming and outgoing edges { each node is in-
formed about his `next-door'-neighborhood and can quickly answer questions
such as `Are there any outgoing next-edges leaving you?' 6 . Graph productions
and graph transactions have been implemented as C++-functions using the
low-level transaction-mechanism of Poet.
To realize the graphical acquisition tools described in section 2 the AppKit-
Objective-C libraries of NeXTSTEP [19] were used allowing comfortable
programming of complex graphical user interfaces. Rules, which have been
dened with the RuleEditor, are parsed and translated to Clips with a
compiler generated by Yacc and Ox [20,21].
7 Related Work
The knowledge-based system TheMPO clearly stands in theOncocin/Opal
tradition. Oncocin [14] is an expert system supporting therapy planning and
monitoring in adult oncology, and provides a graphical acquisition tool (Opal
6Adjacency-matrices should be considered as an appropriate graph representation
when the question frequently arises whether a path exists between two given nodes
n1 and n2. In the context of protocol and patient graphs this problem type is less
important than asking for edges of a given label leaving from or pointing to a given
node n (for more details about graph representation and graph algorithms see [18]).
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[22]) for protocol authoring similar to the tools described in section 2. How-
ever, Opal and TheMPO for example dier in the acquisition of rule knowl-
edge. Opal provides several structured forms for important classes of rule
knowledge which have been considered to be important in the domain; with
these forms, the user can easily specify rules of a predened structure. In the
domain of pediatric oncology, however, the structure of rule knowledge used
for stratication and therapy modication is too heterogeneous to be covered
by an acceptable number of acquisition forms. Therefore, a rule editor has
been implemented allowing the specication of rule knowledge not restricted
to a small number of rule classes. Concerning the patient records of the two
systems, the temporal network Tnet/Etnet [23] of the Oncocin-record is
comparable to the temporal graph of the TheMPO-patient record shown in
gure 12. However, the Oncocin-record is not able to explicitly represent
causal relationships between patient data, as it is for example shown in gure
12, where the causal context is represented, that Asparaginase has been
discontinued because of a detected hyperglycemia-trend. In the domain of
protocol-directed pediatric oncology, where signicant therapy modications
may result in removing the patient from the clinical trial associated with the
protocol, the explicit representation of the medical decision process has been
considered necessary.
Catipo (Computer Aided Therapy in Pediatric Oncology) [4] is a
system for automated chemotherapy calculation in the domain of childhood
cancer. It has a knowledge base for the dierent types of chemotherapy, and
an alpha-numerical editor for chemotherapy denition. However, it does not
provide modules supporting other types of therapy (e.g. radiation), has no
representation of the protocol structure (such as the one in gure 1), and
does not include a persistent patient record. Its encouraging results in clinical
routine chemotherapy calculation { it is currently used in about 15 child-
hood cancer centers in Germany { have been one of the motivations for the
TheMPO-project.
Sepia [24] is an expert system for monitoring patients hospitalized in hemato-
oncology departments to undergo clinical protocols. Sepia, which is based on
the control-theory paradigm, provides powerful mechanism for detecting criti-
cal laboratory value trends, for modifying therapy and diagnostic procedures
as a consequence, and for meeting real-time constraints. From a more abstract,
domain-independent point of view, TheMPO and Sepia can be viewed as
complementary systems: TheMPO focuses on elaborate therapy planning
and conguration based on complex standardized protocols, Sepia on the
detection and management of critical situations during protocol-application.
OncoCons (= Oncology Consultant) [25] is a knowledge based system
covering a broad range of functions in the domain of adult oncology. This
includes an oncological record with watch-dog functionality (OncoDoc), a
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module for long-term monitoring (OncoMon), a subsystem for radiotherapy
(OncoCart), and a multimedia-based training and information system (On-
coHelp). Beside the fact, that OncoCons is adapted to the domain of adult
cancer diseases, which signicantly diers from pediatric oncology, TheMPO
focuses on knowledge acquisition and processing aspects, while the Onco-
tools concentrate on an elaborate knowledge-based documentation and train-
ing functionality.
8 Conclusion and Open Problems
This article focused on the acquisition, representation, and processing of on-
cological protocols in the domain of childhood cancer. The knowledge-based
system TheMPO, developed to support physicians in this complex domain,
provides graphical tools for the acquisition of protocol knowledge, a problem-
solver reasoning about adequate therapy steps for a given patient, and a pa-
tient record. TheMPO incorporates several methodologies, as the domain
knowledge in the eld of pediatric oncology is too heterogeneous to be cov-
ered by a single approach. Planning knowledge, for example, is represented
through a semantic network; the complex network transformation processes
driven by knowledge acquisition, problem solving and data entry, are formally
described and controlled by a graph-grammar. Moreover, the network and
graph-grammar representation is realized in an object-oriented manner. For
example, the nodes in the network are instances of classes within an inher-
itance hierarchy, providing public methods for external modules to explore
or modify their attributes or local neighborhood (e.g., a graph-grammar pro-
duction inserting a new node and edge into the semantic network simply in-
vokes an AddNode(aNodeId)- and an InsertEdge(aSourceNodeId, aTargetN-
odeId, anEdgeId)-method of the interface of the Graph-instance representing
the network, which then handles the internal updating of the global node
list and the aected adjacency-lists). On the other side, rule representation
and data-driven rule processing, which is of importance for the subdomain
of toxicity management, can be expressed and processed in a more natural
and ecient way by a rule-based language and interpreter. In this case, the
forward-chaining Clips-environment has been chosen, as Clips is easy to in-
tegrate into a C++-based application. Therefore, rules valid in the context of
a particular chemotherapy are stored in the RuleSet-node of this chemothe-
rapy, and are loaded by the Clips-interpreter (the interpreter itself is invoked
by the global problem-solver as a subprocess), when a patient is treated with
this chemotherapy.
However, there are several problems and shortcomings which have to be ad-
dressed in the future. First of all, the critical tool in the suite of acquisition
tools is the RuleEditor, as it has not been proved yet whether this com-
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plex experimental tool can really be used by physicians. The complexity is
caused not mainly by building up the rule itself than by dealing with the error
messages of the rule parser. Future eorts have to concentrate on informative
and suggestive error messages of the parser understandable not only for com-
puter scientists. Furthermore, as a powerful semantic check of rules detecting
for instance subsuming or conicting rules has not yet been developed, work
has to be done addressing this important topic. Another shortcoming of the
system is the inability to deal with complex trend knowledge which is of par-
ticular importance for an eective monitoring. Currently, TheMPO does not
provide a mechanism to acquire, represent and process trend knowledge more
complex than for instance the obviously simple hyperglycemia trend of gure
12. Future work, based on the works of Shahar [26] and Kahn [27], has to
concentrate on this topic.
Furthermore, as large hospitals are characterized by extremely heterogeneous
electronic information processing environments, additional work has to be
done to integrate the system into existing,Windows/SQL-dominated clinical
networks and information systems.
A rst phase of clinical testing and evaluation of the system has started in
the begin of 1997 at the Children Hospital of the University of Mainz. The
rst step of evaluation has focused on the testing of the modules calculating
a chemotherapy such as the one shown in gure 14, where the system has
suggested the dosages of one of the involved drugs. This testing has been done
by the following substeps:
{ First of all, the systems had to recalculate a signicant number of former
chemotherapy treatments, which have already been applied to former pa-
tients, and which have been considered to be correct. The results of the
recalculation then have been compared with the dosages that have been
given. The basic intention of this step was to detect a number of relatively
trivial system bugs, which have not been detected in the computer labora-
tory when using only a few generated test data of ctitious patients, and
to demand the time of physicians only minimally, as this step was done
mainly by the developers of the system. Furthermore, during this step, the
relatively simple, though time-consuming acquisition of the chemotherapy
knowledge was mainly done by the developers too (with the TherapyEdi-
tor). The latter is possible, as protocols specify chemotherapy treatments
precisely.
{ The next step then consisted of calculating chemotherapy treatments of
patients (currently being hospitalized at that time) simultaneously by the
program and by an experienced physician, and by comparing the results.
Again, chemotherapy acquisition has been done by the developers, to reduce
the amount of work for the physicians during this step. Currently, the results
of these two steps are analyzed.
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{ If the modules calculating the chemotherapy have been considered to work
correct and to provide an ergonomic user interface, the next step consists
of calculating the drug dosages of current patients by the system solely
(including a nal plausibility inspection of the dosages by the physician).
As the manual calculation of complex chemotherapy units is one of the most
time-consuming activities for physicians, a success concerning this step has
to be viewed as being critical for the acceptance and motivation of physicians
in using the complex system.
{ If the physicians accept the chemotherapy calculation modules, testing shifts
to acquisition aspects. First of all, the acquisition of the chemotherapy
knowledge (with the TherapyEditor) through physicians is tested, and
it is analyzed how to optimize this process concerning user interaction and
ergonomic issues.
If the chemotherapy modules (including the TherapyEditor) as the core
of the system have been proved to be correct and have been accepted by
the medical sta, evaluation is extended to the more complex tools such as
the ProtocolEditor, the RuleEditor, and the problem solvers process-
ing risk group assignments and suggesting new therapy units after recovering
phases.
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Summary
This article introduced the knowledge-based system TheMPO (Therapy
Management in Pediatric Oncology), which supports protocol-directed ther-
apy planning and conguration in pediatric oncology. TheMPO provides
several graphical acquisition tools for knowledge base authoring, which hide
the internal representation language and enable the physician to edit proto-
cols and units of therapy in a diagram-oriented way known from the paper-
based protocols. The internal protocol representation approach is mainly based
on semantic networks, but also uses a rule-based approach for specic sub-
sets of protocol knowledge (e.g., toxicity detection and management). Graph-
grammars have been used to formally describe the class of legal protocol
graphs. A problem-solver, specied with the CML-modeling language, and
implemented in C++/Clips suggests patient-adapted therapy plans and de-
tects critical toxicity situations. The network/graph-grammar approach of the
protocol knowledge base has been used for the corresponding patient record
too, as the course of treatment of a particular patient can be viewed as a graph
build around a path through the protocol network. Beside storing the diag-
nostic and therapeutic procedures, the patient record of TheMPO focuses
on the explicit representation of semantic relationships between medical data,
e.g. the record may represent the causal context that a Cisplatin-infusion
has been reduced because of a pathological creatinine-clearance value. The
acquisition of contexts is also done by graphical tools. The next main steps
have to concentrate on the analysis of the rst clinical evaluation phase which
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